Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Trends in the prescription of oral anticoagulants in adults with COPD in UK Primary Care (2010-2022)

FY 2023-24

Summary
Background: Chronic Obstructive Pulmonary disease (COPD) is commonly associated with cardiovascular conditions requiring additional pharmacological treatment. In particular, oral anticoagulants (OAC) are commonly prescribed to patients with cardiac comorbidities, such as atrial fibrillation (AF), and for the prevention of venous thromboembolism. However, there is a lack of information on the prescribing trends of OACs, including vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) in patients with COPD. Methods: The objective of this study is to quantify the incidence (number of new cases) of AF in patients with COPD and to describe the patterns of OACs prescribed to these patients. In addition, we will describe the patient characteristics associated with a first prescription of VKAs as compared with DOACs. Using the United Kingdom Clinical Practice Research Datalink, the yearly incidence rates of AF in adults with COPD, as well as those who were subsequently prescribed an OAC in the UK between 2010 and 2022, will be calculated using a Poisson model. This model will also be used to calculate prescription rates of VKAs and DOACs separately, and for individual DOACs (apixaban, dabigatran, edoxaban, rivaroxaban). We will also describe prescription pattern according to age, sex, COPD severity, and CHA2DS2-VASc score, and HAS-BLED score in stratified analyses. Relevance: The results of this study will provide a comprehensive description of the prescription trends over time of OACs in patients with multimorbid COPD, and the profile of patients prescribed these drugs. This information can direct and identify the need for further research to identify best practices for treating patients with COPD and comorbid cardiovascular conditions.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
506363
Name
Murray Brianna
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Trends in the prescription of oral anticoagulants in adults with COPD in UK Primary Care (2010-2022)
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anticoagulants; Atrial Fibrillation; Cohort Study; Copd; Databases; Drug Utilization
Abstract
Background: Chronic Obstructive Pulmonary disease (COPD) is commonly associated with cardiovascular conditions requiring additional pharmacological treatment. In particular, oral anticoagulants (OAC) are commonly prescribed to patients with cardiac comorbidities, such as atrial fibrillation (AF), and for the prevention of venous thromboembolism. However, there is a lack of information on the prescribing trends of OACs, including vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) in patients with COPD. Methods: The objective of this study is to quantify the incidence (number of new cases) of AF in patients with COPD and to describe the patterns of OACs prescribed to these patients. In addition, we will describe the patient characteristics associated with a first prescription of VKAs as compared with DOACs. Using the United Kingdom Clinical Practice Research Datalink, the yearly incidence rates of AF in adults with COPD, as well as those who were subsequently prescribed an OAC in the UK between 2010 and 2022, will be calculated using a Poisson model. This model will also be used to calculate prescription rates of VKAs and DOACs separately, and for individual DOACs (apixaban, dabigatran, edoxaban, rivaroxaban). We will also describe prescription pattern according to age, sex, COPD severity, and CHA2DS2-VASc score, and HAS-BLED score in stratified analyses. Relevance: The results of this study will provide a comprehensive description of the prescription trends over time of OACs in patients with multimorbid COPD, and the profile of patients prescribed these drugs. This information can direct and identify the need for further research to identify best practices for treating patients with COPD and comorbid cardiovascular conditions.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Murray, Brianna
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~